Minimal residual disease (MRD) detection using a tumour naive circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

被引：1
|
作者：
Day, D. [1 ,2 ]
Starus, A. [3 ]
Gebski, V. [4 ]
Simes, J. [4 ]
Hayes, T. [5 ]
Padinharakam, S. [6 ]
Strickland, A. H. [1 ,2 ]
Briscoe, K. [7 ]
Varma, S. [8 ]
Barnet, M. [9 ]
Jackson, C. [10 ]
Horvath, L. G. [11 ]
Price, T. J. [12 ,13 ]
Tebbutt, N. [14 ]
Karki, B. [15 ]
Diakos, C. I. [16 ]
Chia, J. [17 ]
Toh, H. C. [17 ]
Jones, F. S. [3 ]
Segelov, E. [18 ]
机构：
[1] Monash Hlth, Dept Oncol, Clayton, Vic, Australia
[2] Dept Med, Clayton, Vic, Australia
[3] Sysmex Inost Inc, Med Affairs, Baltimore, MD USA
[4] Univ Sydney, NHMRC Clin Trial Ctr, Sydney, NSW, Australia
[5] Southwest Oncol, Med Oncol, Warrnambool, Vic, Australia
[6] Launceston Gen Hosp, Specialist Care Australia, Launceston, NSW, Australia
[7] Mid North Coast Canc Inst, Med Oncol, Coffs Harbour, NSW, Australia
[8] Townsville Hosp, Dept Oncol, Douglas, Qld, Australia
[9] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[10] Dunedin Publ Hosp, Dept Med Oncol, Dunedin, New Zealand
[11] Chris OBrien Lifehouse, Med Oncol, Camperdown, NSW, Australia
[12] Univ Adelaide, Med Oncol, Adelaide, SA, Australia
[13] Lyell McEwin Hosp, Elizabeth Vale, SA, Australia
[14] Austin Hlth, Dept Oncol, Heidelberg, Vic, Australia
[15] Toowoomba Gen Hosp, Toowoomba Hosp Canc Ctr Serv, Clayton, Vic, Australia
[16] Genesis Care North Shore, Dept Med Oncol, St Leonards, NSW, Australia
[17] NCCS, Dept Med Oncol, Singapore, Singapore
[18] Univ Bern, Dept Clin Res, Fac Med, Bern, Switzerland
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1777
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
586P
引用
收藏
页码：S426 / S427
页数：2
相关论文
共 50 条
  • [41] Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
    Taieb, J.
    Taly, V.
    Vernerey, D.
    Bourreau, C.
    Bennouna, J.
    Faroux, R.
    Desrame, J.
    Bouche, O.
    Borg, C.
    Egreteau, J.
    Mineur, L.
    Lepere, C.
    Deplanque, G.
    Mulot, C.
    Louvet, C.
    Mabro, M.
    Ychou, M.
    de Gramont, A.
    Andre, T.
    Laurent-Puig, P.
    ANNALS OF ONCOLOGY, 2019, 30 : 867 - 867
  • [42] TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
    Nakamura, Y.
    Okamoto, W.
    Kato, T.
    Hasegawa, H.
    Kato, K.
    Iwasa, S.
    Esaki, T.
    Komatsu, Y.
    Masuishi, T.
    Nishina, T.
    Nomura, S.
    Fukui, M.
    Matsuda, S.
    Sato, A.
    Fujii, S.
    Odegaard, J. I.
    Olsen, S.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 199 - +
  • [43] Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, epigenomic assay in patients with early-stage breast cancer - results from the Success A study
    Friedl, Thomas W. P.
    Rack, Brigitte
    Fasching, Peter Andreas
    Hartkopf, Andreas
    Tesch, Hans
    Lorenz, Ralf
    Heinrich, Georg
    Blohmer, Jens-Uwe
    Fehm, Tanja
    Mueller, Volkmar
    Schneeweiss, Andreas
    Beckmann, Matthias
    Ruebner, Matthias
    Harbeck, Nadia
    Pantel, Klaus
    Dustin, Derek
    Cai, Mingyang
    Janni, Wolfgang
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 261 - 261
  • [44] Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay
    Janni, W.
    Rack, B.
    Friedl, T. W. P.
    Hartkopf, A. D.
    Wiesmueller, L.
    Pfister, K.
    Mergel, F.
    Fink, A.
    Braun, T.
    Mehmeti, F.
    Uhl, N.
    De Gregorio, A.
    Huober, J.
    Fehm, T.
    Mueller, V.
    Rich, T. A.
    Dustin, D. J.
    Zhang, S.
    Huesmann, S. T.
    ESMO OPEN, 2025, 10 (04)
  • [45] Circulating tumor DNA (ctDNA) as a minimal residual disease (MRD) assessment and recurrence risk in patients undergoing curative intent resection with or without adjuvant chemotherapy in colorectal cancer: A systematic review and meta-analysis.
    Chidharla, Anusha
    Rapoport, Eliot
    Agarwal, Kriti
    Linares, Brenda
    Chakrabarti, Sakti
    Kasi, Anup
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
    Flach, S.
    Howarth, K.
    Hackinger, S.
    Pipinikas, C.
    Mclay, K.
    Marsico, G.
    Walz, C.
    Reichel, C. A.
    Gires, O.
    Canis, M.
    Baumeister, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S795 - S796
  • [47] Comparing single-target and multitarget approaches for postoperative circulating tumour DNA detection in stage II-III colorectal cancer patients
    Henriksen, Tenna Vesterman
    Reinert, Thomas
    Rasmussen, Mads Heilskov
    Demuth, Christina
    Love, Uffe Schou
    Madsen, Anders Husted
    Gotschalck, Kare Andersson
    Iversen, Lene Hjerrild
    Andersen, Claus Lindbjerg
    MOLECULAR ONCOLOGY, 2022, 16 (20) : 3654 - 3665
  • [48] Novel clinical decision support (CDS) system optimizing adjuvant chemotherapy (ACT) for colorectal cancer (CRC) by integrating deep learning and circulating tumor DNA (ctDNA) molecular residual disease (MRD): GALAXY histotyping
    Nakamura, Y.
    Kildal, W.
    Misumi, T.
    Pradhan, M.
    Watanabe, J.
    Skrede, O-J
    Kotani, D.
    Raedt, S. D.
    Bando, H.
    Kalsnes, J.
    Taniguchi, H.
    Liestol, K.
    Takemasa, I.
    Hveem, T. S.
    Kato, T.
    Novelli, M.
    Oki, E.
    Kerr, D. J.
    Yoshino, T.
    Kleppe, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S457 - S458
  • [49] Potential utility of methylation levels detected from circulating tumor DNA (ctDNA) in predicting molecular residual disease (MRD) in patients with resected non-small cell lung cancer (NSCLC).
    Hu, Hong
    Li, Hang
    Ma, Zelin
    Xiang, Jiaqing
    Zhang, Yawei
    Lizaso, Analyn
    Hou, Ting
    Guan, Xiaoqian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients
    Vessies, Daan C. L.
    Schuurbiers, Milou M. F.
    van der Noort, Vincent
    Schouten, Irene
    Linders, Theodora C.
    Lanfermeijer, Mirthe
    Ramkisoensing, Kalpana L.
    Hartemink, Koen J.
    Monkhorst, Kim
    van den Heuvel, Michel M.
    van den Broek, Daan
    MOLECULAR ONCOLOGY, 2022, 16 (14) : 2719 - 2732
12345